Literature DB >> 21308703

Celecoxib determination in different layers of skin by a newly developed and validated HPLC-UV method.

Fabíola Silva Garcia Praça1, Maria Vitória Lopes Badra Bentley, Marilisa Guimarães Lara, Maria Bernadete Riemma Pierre.   

Abstract

A simple, rapid and sensitive analytical procedure for the measurement of celecoxib (CXB) levels in skin samples after in vitro penetration studies was developed and validated. In vitro permeability studies in porcine skin were performed for quantification of CXB at different layers of skin, the stratum corneum (SC) and epidermis plus dermis (EP + D) as well as in the acceptor solution (AS) to assess CXB permeation through skin. CXB was quantified by HPLC using a C18 column and UV detection at 251 nm. The mobile phase was methanol-water 72:28 (v/v) and the flow-rate was 0.8 mL/min. The CXB retention time was 5 min. The assay was linear for CBX in the concentration range of 0.1-3.0 μg/mL in the AS (drug permeated through skin) and 5.0-50.0 μg/mL for drug retained in SC and [EP + D] in vitro. The linear correlation coefficients for the different calibration curves were equal or greater than 0.99. Intra- and inter-assay variabilities were below 8.0%. Extraction of CXB from skin samples showed recoveries higher than 95.0% after 15 min of ultrasonic sound and centrifugation at 2500 rpm for 3 min. The method was considered appropriate for the assay of CXB in skin samples, after in vitro cutaneous penetration studies.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Celecoxib; HPLC; skin; tape stripping; validation method; vertical diffusion cell

Mesh:

Substances:

Year:  2011        PMID: 21308703     DOI: 10.1002/bmc.1596

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  3 in total

1.  Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.

Authors:  Eder André Estracanholli; Fabíola Silva Garcia Praça; Ana Beatriz Cintra; Maria Bernadete Riemma Pierre; Marilisa Guimarães Lara
Journal:  AAPS PharmSciTech       Date:  2014-07-01       Impact factor: 3.246

2.  2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.

Authors:  Ai Fujita; Fumi Takahashi-Yanaga; Sachio Morimoto; Tatsuya Yoshihara; Masaki Arioka; Kazunobu Igawa; Katsuhiko Tomooka; Sumio Hoka; Toshiyuki Sasaguri
Journal:  Hypertens Res       Date:  2016-09-15       Impact factor: 3.872

3.  Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway.

Authors:  Issei Egashira; Fumi Takahashi-Yanaga; Risa Nishida; Masaki Arioka; Kazunobu Igawa; Katsuhiko Tomooka; Yoshimichi Nakatsu; Teruhisa Tsuzuki; Yusaku Nakabeppu; Takanari Kitazono; Toshiyuki Sasaguri
Journal:  Cancer Sci       Date:  2016-12-01       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.